PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignanciesYonghui Sun, Yu Rao, Xingwang Zhao et al.|Cell Research|2018Cited by 280
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapyYu Rao, Xuejing Shao, Tianbai Zhong et al.|Nature Chemical Biology|2021Cited by 162
Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACsHongying Gao, Yu Rao, Yue Wu et al.|ACS Medicinal Chemistry Letters|2019Cited by 85
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of <i>Plasmodium falciparum</i> (<i>Pf</i>NDH2) with Small Molecule To Eliminate Drug-Resistant MalariaYiqing Yang, Maojun Yang, You Yu et al.|Journal of Medicinal Chemistry|2017Cited by 77
Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A ReductaseMeixin Li, Yu Rao, Yiqing Yang et al.|Journal of Medicinal Chemistry|2020Cited by 62